CCR5 and neoplasm: mCCR5-Ig fusion protein, anti-CCR5 antibody, or even CCL5-neutralizing mAb were all found that could reduce the number and suppressive capacity of tumor infiltration MDSCs, prevent the tumor metastasis, promote the survival of B16 tumor-bearing mouse and even improve the efficacy of anti-PD-1 tumor therapy (102, 103).